title: Comparison of (64)Cu-complexing bifunctional chelators for radioimmunoconjugation: labeling efficiency, specific activity, and in vitro/in vivo stability.
abstract: High radiolabeling efficiency, preferably to high specific activity, and good stability of the radioimmunoconjugate are essential features for a successful immunoconjugate for imaging or therapy. In this study, the radiolabeling efficiency, in vitro stability, and biodistribution of immunoconjugates with eight different bifunctional chelators labeled with (64)Cu were compared. The anti-CD20 antibody, rituximab, was conjugated to four macrocyclic bifunctional chelators (p-SCN-Bn-DOTA, p-SCN-Bn-Oxo-DO3A, p-SCN-NOTA, and p-SCN-PCTA), three DTPA derivatives (p-SCN-Bn-DTPA, p-SCN-CHX-A″-DTPA, and ITC-2B3M-DTPA), and a macrobicyclic hexamine (sarcophagine) chelator (sar-CO2H) = (1-NH2-8-NHCO(CH2)3CO2H)sar where sar = sarcophagine = 3,6,10,13,16,19-hexaazabicyclo[6.6.6]icosane). Radiolabeling efficiency under various conditions, in vitro stability in serum at 37 °C, and in vivo biodistribution and imaging in normal mice over 48 h were studied. All chelators except sar-CO2H were conjugated to rituximab by thiourea bond formation with an average of 4.9 ± 0.9 chelators per antibody molecule. Sar-CO2H was conjugated to rituximab by amide bond formation with 0.5 chelators per antibody molecule. Efficiencies of (64)Cu radiolabeling were dependent on the concentration of immunoconjugate. Notably, the (64)Cu-NOTA-rituximab conjugate demonstrated the highest radiochemical yield (95%) under very dilute conditions (31 nM NOTA-rituximab conjugate). Similarly, sar-CO-rituximab, containing 1/10th the number of chelators per antibody compared to that of other conjugates, retained high labeling efficiency (98%) at an antibody concentration of 250 nM. In contrast to the radioimmunoconjugates containing DTPA derivatives, which demonstrated poor serum stability, all macrocyclic radioimmunoconjugates were very stable in serum with <6% dissociation of (64)Cu over 48 h. In vivo biodistribution profiles in normal female Balb/C mice were similar for all the macrocyclic radioimmunoconjugates with most of the activity remaining in the blood pool up to 48 h. While all the macrocyclic bifunctional chelators are suitable for molecular imaging using (64)Cu-labeled antibody conjugates, NOTA and sar-CO2H show significant advantages over the others in that they can be radiolabeled rapidly at room temperature, under dilute conditions, resulting in high specific activity.
authors.affiliation: King's College London , Division of Imaging Sciences and Biomedical Engineering, 4th Floor Lambeth Wing, St. Thomas' Hospital, SE1 7EH, London, United Kingdom.
authors.forename: Maggie S
authors.initials: MS
authors.lastname: Cooper
authors.forename: Michelle T
authors.initials: MT
authors.lastname: Ma
authors.forename: Kavitha
authors.initials: K
authors.lastname: Sunassee
authors.forename: Karen P
authors.initials: KP
authors.lastname: Shaw
authors.forename: Jennifer D
authors.initials: JD
authors.lastname: Williams
authors.forename: Rowena L
authors.initials: RL
authors.lastname: Paul
authors.forename: Paul S
authors.initials: PS
authors.lastname: Donnelly
authors.forename: Philip J
authors.initials: PJ
authors.lastname: Blower
mesh_terms: D000818:Animals; D058846:Antibodies, Monoclonal, Murine-Derived / Q000737:chemistry* / Q000493:pharmacokinetics; D002614:Chelating Agents / Q000737:chemistry* / Q000493:pharmacokinetics; D003301:Copper Radioisotopes / Q000737:chemistry* / Q000493:pharmacokinetics; D004355:Drug Stability; D005260:Female; D018796:Immunoconjugates / Q000737:chemistry* / Q000493:pharmacokinetics; D007553:Isotope Labeling; D047028:Macrocyclic Compounds / Q000737:chemistry / Q000493:pharmacokinetics; D051379:Mice; D008807:Mice, Inbred BALB C; D049268:Positron-Emission Tomography; D019275:Radiopharmaceuticals / Q000737:chemistry* / Q000493:pharmacokinetics; D000069283:Rituximab; D014018:Tissue Distribution
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D002614:Chelating Agents; D003301:Copper Radioisotopes; D018796:Immunoconjugates; D047028:Macrocyclic Compounds; D019275:Radiopharmaceuticals; D000069283:Rituximab